Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS

This article was originally published in The Pink Sheet Daily

02 Jul 2010
News

The Pink Sheet Daily pinkeditor@informa.com

Executive Summary

The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS070920

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS070920

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS

News

Executive Summary

Related Content

When To End A REMS? Soliris Review Stirs Debate On How To Scale Back

Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes

The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins

FDA Gives Firms With RiskMAP Drugs 6 Months To Submit Strategy Proposals

FDA Gives Firms With RiskMAP Drugs 6 Months To Submit Strategy Proposals

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert